血清甲胎蛋白、甲胎蛋白异质体、异常凝血酶原、鳞状细胞癌抗原联合检测对肝细胞癌的诊断价值

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (0 KB) HTML (35 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究血清甲胎蛋白（AFP）、甲胎蛋白异质体（AFP-L3）、异常凝血酶原（DCP）、鳞状细胞癌抗原（SCCA）联合检测在肝细胞癌（HCC）的诊断价值。方法选取2017年5月～2019年5月我院就诊的40 例HCC 患者、42 例肝硬化（LC）患者、54 例慢性乙型肝炎（CHB）患者、50 例健康体检者的血清学指标及临床资料。检测各组受试者血清AFP、AFP-L3、DCP、SCCA 的水平，比较4 项血清标志物单独及联合诊断的工作特征曲线下面积。结果与健康组比较，HCC 组、LC 组、CHB 组血清AFP、AFP-L3、DCP、SCCA 水平升高，差异有统计学意义（P＜0.01）；与LC组、CHB 组比较，HCC 组血清AFP、AFP-L3、DCP、SCCA 水平升高，差异有统计学意义（P＜0.01）。 4 项指标联合检测的曲线下面积均大于四者的单独检测。结论 AFP、AFP-L3、DCP、SCCA 联合检测具有较高诊断效能，可为早期诊断HCC 提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李薇薇

关键词 ：肝细胞癌, 甲胎蛋白类, 异常凝血酶原, 鳞状细胞癌抗原, 诊断

Abstract：Objective To explore the diagnostic value of combined detection of serum alpha-fetoprotein (AFP), alphafetoprotein heterogeneity-L3 (AFP-L3), des-gamma-carboxyprothrombin (DCP), squamous cell carcinoma antigen (SCCA) in hepatocellular carcinoma (HCC).Methods From May 2017 to May 2019, 40 patients with HCC, 42 patients with liver cirrhosis (LC), 54 patients with chronic hepatitis B (CHB), and 50 healthy people were selected from our hospital for serological indicators and clinical data.The levels of serum AFP, AFP-L3, DCP and SCCA were measured in each group, and the area under the curve of receiver operating characteristic (ROC) of 4 serum markers, alone or in combination, were compared.Results The levels of AFP, AFP-L3, DCP and SCCA in HCC group, LC group and CHB group were higher than those in the healthy group, the differences were statistically significant (P＜0.01).The levels of AFP, AFP-L3, DCP and SCCA in HCC group were higher than those in LC group and CHB group, the differences were statistically significant (P＜0.01).The area under ROC curve of the combined detection were all higher than those of four individual detections.Conclusion The combined detection of AFP, AFP-L3, DCP, and SCCA has a high detection efficiency, and provide a reliable reference for the early diagnosis of HCC.

Key words： Hepatocellular carcinoma Alpha-fetoproteins Des-gamma-carboxyprothrombin Squamous cell carcinoma antigen Diagnosis

作者简介: 李薇薇（1968-），女，本科，副主任技师，主要从事临床检验工作，擅长临床医学检验及慢性病实验室诊断

引用本文:

李薇薇. 血清甲胎蛋白、甲胎蛋白异质体、异常凝血酶原、鳞状细胞癌抗原联合检测对肝细胞癌的诊断价值[J]. 中国当代医药, 2020, 27(22): 94-96转100.
LI Wei-wei. Diagnostic value of combined detection of serum alpha-fetoprotein, alphafetoprotein heterogeneity-L3, des-gamma-carboxyprothrombin, squamous cell carcinoma antigen in hepatocellular carcinoma. 中国当代医药, 2020, 27(22): 94-96转100.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I22/94

[1]	Llovet JM，Burroughs A，Bruix J.Hepatocellular carcinoma[J].Lancet，2003，362（9399）：1907-1917.
[2]	中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范（2017年版）[J].中华消化外科杂志，2017，16（7）：635-647.
[3]	刘成海，危北海，姚树坤.肝硬化中西医结合诊疗共识[J].中国中西医结合消化杂志，2011，19（4）：277-279.
[4]	王贵强，王福生，成军，等.慢性乙型肝炎防治指南（2015年更新版）[J].临床肝胆病杂志，2015，31（12）：1941-1960.
[5]	Galle PR，Foerster F，Kudo M，et al.Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J].Liver Int，2019，39（12）：2214-2229.
[10]	关贵文，姚明解，钱相君，等.AFP 和AFP-L3%联合检测在肝细胞癌诊断中的应用价值[J].临床肝胆病杂志，2019，35（7）：1514-1519.
[17]	邹珍珍，高致远，童林，等.联合检测血清AFP-L3 和DCP 在肝细胞癌中的应用[J].中国现代普通外科进展，2019，22（9）：735-737.
[18]	张明跃，陈浩.AFP、DCP 和AFP-L3%联合检测对肝细胞肝癌的诊断价值[J].癌症进展，2019，17（6）：719-721.
[6]	Seo SI，Kim HS，Kim WJ，et al.Diagnostic value of PIVKA-Ⅱand alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma[J].World J Gastroenterol，2015，21（13）：3928-3935.
[7]	Choi JY，Jung SW，Kim HY，et al.Diagnostic value of AFPL3 and PIVKA-Ⅱin hepatocellular carcinoma according to total-AFP[J].World J Gastroenterol，2013，19（3）：339-346.
[8]	Li D，Mallory T，Satomura S.AFP-L3：a new generation of tumor marker for hepatocellular carcinoma[J].Clin Chim Acta，2001，313（1-2）：15-19.
[9]	Kumada T，Toyoda H，Tada T，et al.High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma[J].J Gastroenterol，2014，49（3）：555-563.
[11]	Carr BI，Kanke F，Wise M，et al.Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and desgamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States[J].Dig Dis Sci，2007，52（3）：776-782.
[12]	T suchiya N，Sawada Y，Endo I，et al.Biomarkers for the early diagnosis of hepatocellular carcinoma[J].World J.Gastroenterol，2015，21（37）：10 573-10 583.
[13]	Best J，Bilgi H，Heider D，et al.The GALAD scoring algorithm based on AFP，AFP-L3，and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma[J].Z Gastroenterol，2016，54（12）：1296-1305.
[14]	Guido M，Roskams T，Pontisso P，et al.Squamous cell carcinoma antigen in human liver carcinogenesis[J].J Clin Pathol，2008， 61（4）：445-447.
[15]	Liu CH，Gil-Gómez A，Ampuero J，et al.Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma：A meta-analysis[J].Liver Int，2018，38（10）：1820-1831.
[16]	Trerotoli P，Fransvea E，Angelotti U，et al.Tissue expression of Squamous Cellular Carcinoma Antigen（SCCA）is inversely correlated to tumor size in HCC[J].Mol Cancer，2009，（8）：29.